SGMT Sagimet Biosciences Inc: Price-to-Projected Revenue Ratio

Sagimet Biosciences - graphic logo of issuer SGMT

High trial uncertainty and a revenue deficit create significant risks for Sagimet Biosciences (SGMT). The forward P/S trend visualizes these expectations, where the value 50.90 serves as the baseline for the current valuation. The company is diversifying its portfolio by developing treatments for acne and liver pathologies, while R&D cost optimization is achieved by outsourcing molecule testing to third-party contractors.

Sagimet Biosciences Inc. - SGMT Market Cap to Expected Sales Ratio (period 03/26/2024 - 11/16/2024)

Summary analytical data breakdowns for sagimet.com (SGMT)

- market price and analyst price targets:
Comprehensive company analysis:Sagimet Biosciences, Inc. SGMT
Original product of Sagimet Biosciences

Driven by breakthrough clinical successes in liver therapy, Sagimet Biosciences (SGMT) is perceived by the market as a future industry leader with significant reputational capital. By analyzing the trajectory of the forward P/S ratio, investors can determine the company's current valuation relative to expected revenue, allowing for a real-time assessment of market confidence in the business's scaling pace without waiting for quarterly reports.

Competitors of Sagimet Biosciences

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|Crinetics Corp (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio newamsterdampharma.com (NAMS)|Forward Price-to-Revenue Multiple soleno.life SLNO|Forward P/S Multiple FOLD (amicusrx.com)|Market Cap to Expected Sales Ratio 89bio (ETNB)|Agios - Forward P/S Multiple|Structure Corp - Price to Expected Revenue Ratio|mimedx.com (MDXG) - Price-to-Projected Revenue Ratio|Future Price to Revenue RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MBX|Price-to-Projected Revenue Ratio Altimmune Pharma (ALT)|Price-to-Projected Revenue Ratio AARD (Aardvark Therapeutics Corp)|Forward P/S Multiple BIOA (BioAge Labs)|Forward P/S Multiple Biomea Fusion BMEA|QNCX: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio